XRAY DENTSPLY SIRONA Inc.

Dentsply Sirona Inc. wins Summary Judgment against Edge Endo and US Endodontics in Patent Infringement Case

Dentsply Sirona Inc. wins Summary Judgment against Edge Endo and US Endodontics in Patent Infringement Case

CHARLOTTE, N.C., June 24, 2020 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona”) (Nasdaq: XRAY), The Dental Solutions Company, today announced that on Tuesday, June 23rd, 2020 the United States District Court for the District of New Mexico, in a ruling by Judge Joseph F. Bataillon, held that EdgeTaper Encore endodontic files sold by US Endodontics and Edge Endo infringe at least three valid claims of patents asserted by Dentsply Sirona Inc.  Judge Bataillon granted Dentsply Sirona’s motion for summary judgment that each of the three patent claims were infringed by EdgeTaper Encore and that Dentsply Sirona’s three patent claims are valid.  The Court also rejected Edge’s request to dismiss Dentsply Sirona’s claim that Edge’s infringement was willful.  A finding of willful infringement allows the Court to award treble damages and attorneys’ fees against an adjudicated infringer.

Dentsply Sirona’s case against Edge and US Endo is scheduled for trial before a jury in Albuquerque, New Mexico beginning on August 17, 2020.  At issue will be Dentsply Sirona’s claims for willful infringement and damages with respect to the three claims that have already been held valid and infringed, as well as Dentsply Sirona’s assertion of infringement with respect to additional patent claims.

About Dentsply Sirona

Dentsply Sirona is the world’s largest manufacturer of professional dental products and technologies, with a 133-year history of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solutions offering including dental equipment and dental consumable products under a strong portfolio of world class brands. The Company also manufactures and markets healthcare consumable products. As The Dental Solutions Company, Dentsply Sirona’s products provide innovative, high-quality and effective solutions to advance patient care and deliver better, safer and faster dentistry. The Company’s shares of common stock are listed in the United States on Nasdaq under the symbol XRAY. Visit for more information about Dentsply Sirona and its products.

Contact Information:

Investors:

John Sweeney, CFA, IRC

Vice President, Investor Relations



Media:

Marion Par-Weixlberger

Vice President Public Relations & Corporate Communications

T +43 (0) 662 2450-588

EN
24/06/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on DENTSPLY SIRONA Inc.

 PRESS RELEASE

Dentsply Sirona Reports Second Quarter 2025 Results

Dentsply Sirona Reports Second Quarter 2025 Results Net sales of $936 million decreased (4.9%), decreased (6.7%) in constant currency including a (3.2%) Byte sales impactGAAP gross margin of 52.4%, GAAP net loss per share of ($0.22)Adjusted gross margin of 55.9%, adjusted EBITDA margin of 21.1%, adjusted EPS of $0.52Executed $550 million debt offeringReaffirmed FY25 outlookLeadership transition with Dan Scavilla appointed CEO effective August 1, 2025 and Matt Garth appointed CFO effective May 30, 2025 CHARLOTTE, N.C., Aug. 07, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Si...

 PRESS RELEASE

Dentsply Sirona Appoints Daniel Scavilla as Chief Executive Officer

Dentsply Sirona Appoints Daniel Scavilla as Chief Executive Officer Provides Select Preliminary Second Quarter 2025 Results and Reaffirms 2025 Outlook CHARLOTTE, N.C., July 21, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or “the Company”) (Nasdaq: XRAY) today announced that Daniel Scavilla, an established business leader with more than three decades of experience in the medical technology and pharmaceutical industries and a current member of the Board of Directors of Dentsply Sirona (the “Board”), has been appointed President and Chief Executive Officer, effective A...

 PRESS RELEASE

Dentsply Sirona to Host Second Quarter Conference Call on August 7th

Dentsply Sirona to Host Second Quarter Conference Call on August 7th CHARLOTTE, N.C., July 10, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will host an investor conference call and live webcast on Thursday, August 7, 2025, at 8:30 am ET to review its financial results for the second quarter of fiscal year 2025. The Company will issue a press release and provide a presentation with summary financial information, which will be made available on the Investors section of the Company’s website at prior to t...

 PRESS RELEASE

Dentsply Sirona Prices Offering of $550 million of Junior Subordinated...

Dentsply Sirona Prices Offering of $550 million of Junior Subordinated Notes CHARLOTTE, N.C., June 05, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the “Company”) (Nasdaq: XRAY) today announced it has priced an offering (the “Offering”) of $550 million aggregate principal amount of its 8.375% Junior Subordinated Notes due 2055 (the “notes”). The Offering is expected to close on June 12, 2025, subject to customary closing conditions. The notes will bear interest at a fixed rate of 8.375% per year until September 12, 2030 (the “First Reset Date”). On and after the Fi...

Moody's Ratings assigns Baa3 rating to Dentsply Sirona's proposed hybr...

Moody's Ratings (Moody's) assigned a Baa3 rating to Dentsply Sirona Inc.'s ("Dentsply Sirona") proposed offering of junior subordinated notes ("hybrid"). At the same time, we affirmed Dentsply Sirona's Baa2 issuer rating, Baa2 senior unsecured rating and Prime-2 commercial paper rating. The outlook ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch